{
    "clinical_study": {
        "@rank": "129487", 
        "arm_group": {
            "arm_group_label": "All patients", 
            "arm_group_type": "Experimental", 
            "description": "Volasertib will be administered as intravenous infusion"
        }, 
        "brief_summary": {
            "textblock": "The present trial will be performed according to an open design to determine the maximum\n      tolerable dose (MTD) by evaluation of dose-limiting toxicity (DLT) of volasertib in\n      paediatric leukaemia and solid tumours in the age group 2 to less than 12 and 12 to less\n      than 18 years. A further objective is to collect data on safety, tolerability, toxicity,\n      efficacy (preliminary activity), pharmacokinetics and pharmacodynamics of volasertib in\n      paediatric cancer patients"
        }, 
        "brief_title": "Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Leukemia", 
            "Neoplasms"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Leukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  paediatric  patients with leukaemia or advanced solid tumours including lymphomas\n             (age 2 - less than 18 years) for whom no further treatment is known\n\n          -  Lansky score > 60 for children 2 to less than 12 years\n\n          -  Karnofsky score > 60 for children aged 12 or older\n\n          -  life expectancy of at least 6 weeks as judged by the investigator\n\n          -  parents or legal guardians have given written informed consent and informed assent\n             suitable for the respective age group obtained\n\n        Exclusion criteria:\n\n          -  patient eligible for other anti-leukaemic therapy with curative intent or effective\n             therapy known for solid tumour therapy\n\n          -  presence of cardiac disease (LVEF by echocardiography less than 25 %)\n\n          -  symptomatic CNS involvement of the malignant disease\n\n          -  primary CNS tumour\n\n          -  inadequate lab parameters\n\n          -  inadequate venous access\n\n          -  QTc prolongation\n\n          -  pregnancy, breastfeeding\n\n          -  other diseases or CTs that might interfere with evaluation of safety"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01971476", 
            "org_study_id": "1230.27", 
            "secondary_id": "2013-001291-38"
        }, 
        "intervention": {
            "arm_group_label": "All patients", 
            "description": "intravenous administration on day 1of a treatment course", 
            "intervention_name": "volasertib", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Wien", 
                        "country": "Austria"
                    }, 
                    "name": "1230.27.43001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gent", 
                        "country": "Belgium"
                    }, 
                    "name": "1230.27.32001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prague", 
                        "country": "Czech Republic"
                    }, 
                    "name": "1230.27.42001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France"
                    }, 
                    "name": "1230.27.33005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France"
                    }, 
                    "name": "1230.27.33003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "1230.27.33002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "1230.27.33004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France"
                    }, 
                    "name": "1230.27.33001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany"
                    }, 
                    "name": "1230.27.49004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany"
                    }, 
                    "name": "1230.27.49001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "K\u00f6ln", 
                        "country": "Germany"
                    }, 
                    "name": "1230.27.49002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Monza", 
                        "country": "Italy"
                    }, 
                    "name": "1230.27.39002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy"
                    }, 
                    "name": "1230.27.39001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "1230.27.31001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bratislava", 
                        "country": "Slovakia"
                    }, 
                    "name": "1230.27.42101 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Belgium", 
                "Czech Republic", 
                "France", 
                "Germany", 
                "Italy", 
                "Netherlands", 
                "Slovakia"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Open, Non-controlled, Dose Escalating Phase I Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Tolerability and Toxicity of Volasertib in Paediatric Patients From 2 Years to Less Than 18 Years of Age With Acute Leukaemia or Advanced Solid Tumour, for Whom no Effective Treatment is Known", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Austria: Medicines and Medical Devices Agency", 
                "Belgium: Federal Agency for Medicinal and Health Products", 
                "Czech Republic: State Institute for Drug Control", 
                "France: Agence Nationale s\u00e9curit\u00e9 m\u00e9dicament et des produits sant\u00e9", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Italy: National Institute of Health", 
                "Netherlands: Central Committee Research Involving Human Subjects", 
                "Slovenia: Agency for Medicinal Products - Ministry of Health", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "number of patients with dose limiting toxicity", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01971476"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "number of patients with hepatic injury as defined as protocol-specified adverse events of special interest", 
                "safety_issue": "No", 
                "time_frame": "up to 6 months"
            }, 
            {
                "measure": "number of patients with clinically relevant lab value changes of calcium (hyper and/or hypocalcaemia) as judged by the investigator and reported as adverse events (Common Terminology Criteria for Adverse Event grade 3 or higher)", 
                "safety_issue": "No", 
                "time_frame": "up to 6 months"
            }, 
            {
                "measure": "number of patients with changes in cardiac activity (prolonged QTc interval) reported as clinically relevant observations ( Adverse Events)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 6 months"
            }, 
            {
                "measure": "number of patients with complete remission (CR)", 
                "safety_issue": "No", 
                "time_frame": "up to 6 months"
            }, 
            {
                "measure": "progression free survival", 
                "safety_issue": "No", 
                "time_frame": "up to one year"
            }, 
            {
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "up to one year"
            }, 
            {
                "measure": "number of patients with complete remission with incomplete blood count (CRi)", 
                "safety_issue": "No", 
                "time_frame": "up to 6 months"
            }, 
            {
                "measure": "number of patients with partial response/remission (PR)", 
                "safety_issue": "No", 
                "time_frame": "up to 6 months"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}